Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) rose 5.1% on Thursday . The stock traded as high as $6.68 and last traded at $6.63, with a volume of 156,759 shares trading hands. The stock had previously closed at $6.31.

ARGS has been the subject of several recent research reports. Stifel Nicolaus lowered their target price on shares of Argos Therapeutics from $16.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, March 30th. Zacks Investment Research upgraded shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a research note on Friday, April 1st. Roth Capital boosted their target price on shares of Argos Therapeutics from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, April 19th. Needham & Company LLC reiterated a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, April 23rd. Finally, FBR & Co reiterated a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, May 14th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Argos Therapeutics has an average rating of “Buy” and an average price target of $11.84.

The stock’s market capitalization is $176.58 million. The stock’s 50-day moving average is $6.20 and its 200 day moving average is $5.50.

Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by $0.01. On average, analysts expect that Argos Therapeutics Inc. will post ($1.74) EPS for the current year.

Argos Therapeutics, Inc (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.